Thursday, 19 Sep 2019

You are here

Two-Fold Increase of Demyelinating Diseases with TNF Inhibition

Despite the potential contributory role of TNF in the pathogenesis of multiple sclerosis, several trials have shown that TNF inhibitor (TNFi) use may lead to worsening of MS, optic neuritis and other demyelinating disorders. This particular safety warning has been in the product label for nearly 15 years, yet little is known about why this happens, how often or what the scope of potentially inducible neurologic disease may be.

Researchers in Denmark investigated this potential association between demyelinating disease and inflammatory bowel disease (IBD) and those receiving TNFi for their IBD.

Using a national population-based cohort, they compared rates of central demyelinating diseases among patients with IBD exposed and unexposed to anti-TNF to data drawn from the Danish Civil Registration System, between January 1, 1999, to December 31, 2012.

The neurologic outcomes of interest were defined as a diagnosis of a central demyelinating disease, which includes multiple sclerosis, optic neuritis, transverse myelitis, and other central demyelinating diseases. Patients with a history of demyelinating diseases and those taking TNFi prior to 1999 or prior to IBD diagnosis were excluded.

Among 54843 IBD patients, 4504 received TNFi and were compared to 16,429 unexposed patients. IBD patients were roughly 40 yrs. of age with a mean disease duration 4.0 years.
When comparing TNFi exposed to unexposed (controls) patients, there were 11 demyelinating events in the exposed and 17 demyelinating events in the unexposed controls. Thus, higher rates were seen in the exposed vs. unexposed (7.5 events per 10000 person-years [95% CI, 4.1-13.5] vs. 3.3 events per 10000 person-years [95% CI, 2.1-5.4]).

Exposed patients with demyelinating disease had 2 cases of multiple sclerosis; 5 optic neuritis; and 4 other central demyelinating diseases. Unexposed patients had 5 multiple sclerosis; 6 optic neuritis; 1 transverse myelitis; 5 other central demyelinating diseases.

Overall, there was a two-fold increased risk of central demyelinating disease when using a TNFi in patients with IBD (HR 2.19 [95% CI, 1.02- 4.71]).

These findings support the potential association and the practice of avoiding TNFi in patients with MS, optic neuritis or other demyelinating disorders. There is little evidence that TNFi worsens or affects other degenerative or inflammatory neurologic disorders.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Checkpoint Inhibitors: Who Gets Myocarditis?

The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.

NSAIDs Mediate Cardiovascular Risk in OA

NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.

Tofacitinib Gets a New Boxed Warning for Blood Clots and Death with Higher Doses

The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR), which is used in patients with ulcerative colitis. 

EHR-Related Adverse Events Usually Involve Medications

Concerns about the unintended risks inherent in electronic health records (EHR) by analysis of EHR–related harms identified from large database of malpractice suits and claims; they found that EHR related adverse events exist, and may be associated with an severe harms and uncommonly, death.

Methotrexate Use Not Linked to Interstitial Lung Disease in RA

People with rheumatoid arthritis have a significant risk of developing interstitial lung disease (RA-ILD), yet there is often a question as to whether methotrexate (MTX) exposure can cause or worsen ILD.  A controlled cohort study suggests that MTX use is not associated with an increased risk of RA-ILD and instead, there is evidence suggesting MTX use may delay the onset of ILD.